CN101180068B - 萃取自石斛的多糖在制备用于治疗哺乳动物自体免疫葡萄膜炎的药物中的用途 - Google Patents
萃取自石斛的多糖在制备用于治疗哺乳动物自体免疫葡萄膜炎的药物中的用途 Download PDFInfo
- Publication number
- CN101180068B CN101180068B CN2006800152597A CN200680015259A CN101180068B CN 101180068 B CN101180068 B CN 101180068B CN 2006800152597 A CN2006800152597 A CN 2006800152597A CN 200680015259 A CN200680015259 A CN 200680015259A CN 101180068 B CN101180068 B CN 101180068B
- Authority
- CN
- China
- Prior art keywords
- cell
- mouse
- decaps
- sequence numbering
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 41
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 41
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 title abstract description 27
- 241001523681 Dendrobium Species 0.000 title abstract description 26
- 206010046851 Uveitis Diseases 0.000 title description 11
- 238000000034 method Methods 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 3
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 230000001982 uveitic effect Effects 0.000 claims description 2
- 238000003808 methanol extraction Methods 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 abstract description 19
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 8
- 230000001939 inductive effect Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 76
- 241000699666 Mus <mouse, genus> Species 0.000 description 61
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 59
- 235000001892 vitamin D2 Nutrition 0.000 description 59
- 239000011653 vitamin D2 Substances 0.000 description 59
- 108020004999 messenger RNA Proteins 0.000 description 30
- 230000000968 intestinal effect Effects 0.000 description 26
- 238000011735 C3H mouse Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 21
- 101710137010 Retinol-binding protein 3 Proteins 0.000 description 20
- 230000036039 immunity Effects 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 108010058846 Ovalbumin Proteins 0.000 description 18
- 229940092253 ovalbumin Drugs 0.000 description 18
- 244000005700 microbiome Species 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 14
- 102000002689 Toll-like receptor Human genes 0.000 description 14
- 108020000411 Toll-like receptor Proteins 0.000 description 14
- 102000004388 Interleukin-4 Human genes 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 12
- 208000034493 Mucous membrane disease Diseases 0.000 description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 11
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 11
- 239000005556 hormone Substances 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 11
- 210000004989 spleen cell Anatomy 0.000 description 11
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 11
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 9
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 108010072788 angiogenin Proteins 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102100022987 Angiogenin Human genes 0.000 description 7
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 7
- 108010062580 Concanavalin A Proteins 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000000541 Defensins Human genes 0.000 description 5
- 108010002069 Defensins Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 210000001986 peyer's patch Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 201000004982 autoimmune uveitis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 210000003158 enteroendocrine cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 108010048996 interstitial retinol-binding protein Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 210000001699 lower leg Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003134 paneth cell Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001428166 Eucheuma Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 108091032917 Transfer-messenger RNA Proteins 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000018568 alpha-Defensin Human genes 0.000 description 1
- 108050007802 alpha-defensin Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940056582 human hair preparation Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- -1 saccharose lipid Chemical class 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种包含由石斛属植物制备而得的多糖的组合物。所述组合物通过诱导口服耐受性与促进先天性免疫力以对自体免疫疾病与黏膜疾病产生作用。
Description
技术领域
本发明是关于对自体免疫疾病与黏膜疾病有效用的组合物、制备方法及其用途,更特别的是所述组合物包含得自于石斛的多糖,且所述组合物的使用方法包含服用取自于石斛的多糖,透过诱导口服耐受性(oral tolerance)与促进先天性免疫力(innate immunity)以对自体免疫疾病与黏膜疾病产生作用。
背景技术
免疫系统的基本性质是免疫耐受性,可分辨自身与非自身分子,因而免疫系统可以保护宿主不受外来病原的侵袭且不对自身攻击。当自身受到免疫系统的攻击时,即形成自体免疫疾病。(Annu.Rev.Med.48:341-351,1997)
目前已证实口服耐受性可应用于治疗自体免疫疾病,包含葡萄膜炎(uveitis)、胶原蛋白所引起的关节炎(collagen-induced arthritis)、佐剂性关节炎(adjuvant arthritis)、系统性红斑性狼疮(Systemic Lupus Erythematosus,SLE)、多发性硬化症(multiple sclerosis)、甲状腺炎、重症肌无力、发炎性肠道疾病(inflammatory bowel disease,IBD)以及第一型糖尿病。(Annals of the New YorkAcademy of Sciences 778(1):217-227,1996)
口服抗原经由食道到了肠相关淋巴组织(gut-associated lymphoid tissue,GALT),所述肠相关淋巴组织是一种非常完整的免疫网状系统。GALT包含绒毛(villi)、固有层(lamina propria)、上皮细胞间淋巴球(intraepitheliallymphocytes)与皮尔氏斑(Peyer’s Patch),其中皮尔氏斑是指散布于绒毛上的淋巴小结。肠道的上皮细胞包含M细胞,负责传送外来的抗原与微生物。M细胞是负责将病原传送至其下免疫细胞,抗原与病原仅能透过M细胞而穿过肠道障蔽。而后,辨识到抗原的上皮间淋巴球会移至皮尔氏斑,以引发免疫反应。在皮尔氏斑,抗原呈现细胞将抗原呈现给淋巴球,而被抗原刺激过的淋巴球细胞经由淋巴管及血液循环,回到远离肠道的全身黏膜组织(如呼吸道等)固有层。
肠道免疫系统中抵御经口服而感染疾病的机制,可分为先天性免疫(innateimmunity)和后天性免疫(adaptive immunity)。病原侵犯人体时,被感染的部位分泌化学激素(chemokine)促进巨噬细胞、单核球(monocytes)、颗粒球和自然杀手细胞进行非特异性的先天性免疫反应。巨噬细胞和颗粒球直接吞噬病原。自然杀手细胞是病毒感染和其他细胞内致病菌感染时最先反应的免疫细胞,自然杀手细胞不仅对标的细胞进行毒杀作用,而且分泌多种细胞激素调节免疫反应,如:IFN-γ、TGF-β、TNF-α、IL-5和IL-10等。巨噬细胞及其他抗原呈现细胞(antigenpresenting cell,APC),如树突状细胞(dendritic cells),利用细胞表面的第二类MHC分子及共刺激分子(co-stimulators),将抗原呈现给T细胞,以进一步活化免疫作用,也就是由T细胞与B细胞分别执行特异性的细胞免疫(cell-mediatedimmunity)和抗体免疫(humoral immunity)反应。黏膜免疫主要受CD4+T细胞分泌细胞激素的调控。第二型辅助T细胞(Th2)所分泌的IL-4、IL-5、IL-6及IL-10参与刺激B细胞产生抗体,第三型辅助T细胞(Th3)主要分泌TGF-β,引起B细胞产生黏膜中最主要的抗体IgA。(Trends Immunol.22:244-247,2004;J.Glin.Invest.106:935-937,2000)
值得注意的是肠道黏膜免疫反应不局限在肠道,而是引起全身黏膜系统的免疫反应。一旦有抗原在小肠引起抗体产生,淋巴细胞经由淋巴液与血液直接作用于直肠、乳汁、肺、生殖道等处,而使得受到作用的组织也都侦测得到抗体,此现象称为共同黏膜免疫系统(common mucosal immune system)。由于共同免疫系统的存在,经由口服途径引起的抗体可遍布全身。经口服途径进入的抗原,若能诱导系统耐受性,或使黏膜表现IgA,就称为口服耐受性(oral tolerance)。口服耐受性包含系统反应(systemic unresponsiveness)和黏膜反应(mucosal responsiveness),前者避免身体发生自体免疫疾病,后者针对特定病原诱发主动的抑制。因此,黏膜免疫系统倾向于抑制系统内发炎的免疫反应,而促进黏膜局部非发炎性IgA的表现(Immunol.Today 18:335-343,1997)。
肠道上皮组织由单层上皮细胞所组成,形成肠道与外来物质(食物、细菌)的屏障,上皮细胞无法允许大分子或微生物通透,且在上皮细胞之间有非常紧密的连结(tight junction),用以阻止小分子进入。结缔组织中包埋的腺窝(crypts)含有干细胞(stem cells),这些干细胞可再生肠上皮细胞。除了再生肠上皮细胞之外,肠干细胞也可以分化为负责分泌肠道黏液(mucin)的杯状细胞(Gobelt cells)与肠内分泌细胞(enteroendocrine cells),以及分泌抗微生物肽(antimicrobialpeptides)。当这些细胞分化后,会往绒毛顶端移动,只有潘氏细胞(Paneth cells)停留在干细胞的区域(J.Clin.Invest.105:1493-1499,2000;Science294:2115-2116,2001)。
可合理的推测:由于肠道上皮细胞特殊的位置,因此对于肠腔中的各式抗原,它可能扮演一个影响免疫系统走向的重要角色。肠道上皮细胞可以像抗原呈现细胞(APCs)一样表现抗原呈现分子(antigen-presenting molecules),以调节肠黏膜中的T细胞反应(Immunol.Today 21:123-128,2000)。研究发现肠道上皮细胞中的抗原呈现分子包括第一类MHC、第二类MHC、以及类似第一类MHC的CD1d(Gastroenterology 124:1420-1431,2003)。MHC class I负责与CD8+T细胞结合,MHC class II负责与CD4+T细胞结合,这两类的抗原呈现分子主要表现于上皮细胞的底侧边细胞膜(basolateral membrane)。CD1d可呈现糖脂质(glycolipid)而活化自然杀手T细胞。这些证据都显示了肠道上皮细胞在黏膜免疫系统中,具有十分重要的地位。
肠道上皮细胞除了担任物理性的屏障(physical barrier),防止病源进入体内,还可以分泌对抗微生物的抗微生物肽(antimicrobial peptides),并且提供讯息给其他细胞(Immunol.Today21:123-128,2000;J.Clin.Invest.95:55-65,1995)。已知肠道中含有一种可对抗微生物感染的肽(antimicrobial peptides),称为防卫素(defensins)。防卫素(defensins)是分子量为3-5kD的蛋白质,可分为阿法-防卫素(α-defensin)家族与贝塔-防卫素(β-defesin)家族,共有八种肽。这些防卫素遍布于人体的上皮细胞,包含口腔、肺脏、肠道等,在不同器官有不同的表现型态(Eur.J.Gastroenterol.Hepatol.13:771-776,2001;Nat.Rev.Immunol.3:710-720,2003)。当肠道受感染时,上皮细胞会表现防卫素(defensins),而防卫素(defensins)具有类似化学激素(chemokine)的功能,吸引自然杀手细胞(NKcells)及树突状细胞(Dendritic cells)到达感染的区域,快速发挥防御作用,这样的作用可视为一种先天性免疫反应(Innate immunity)。防卫素(defensins)不只具有先天性免疫反应的特性,还可以藉由Toll样受体4(toll-like receptor 4)使树突状细胞(Dendritic cells)表现共刺激素(B7.2),促进T细胞增生。因此防卫素与先天性免疫反应及后天性免疫反应之间的连结有关。
另一种重要的抗微生物肽-血管生成素(angiogenins),原本被认为与癌细胞血管新生有关,但后来Hooper在2003年发现,在正常的生理状况下,血管生成素主要由肠道当中的潘氏细胞(Paneth cell)所分泌,平时存在细胞的颗粒(granule)中,可受到脂多糖類(lipopolysaccharide,LPS)的刺激而释放到肠道中。若以无菌鼠(germ-free mice)与带有一般肠内共生菌的老鼠相比,结果显示它受到肠内菌的影响而大量表现。血管生成素与防卫素一样具有增强细胞表面防御功能,及对抗微生物感染的效果(Nat.Immunol.4:269-273,2003)。
除了分泌抗微生物肽抵抗病原的感染之外,肠道上皮细胞也提供许多讯息来调节肠道免疫反应。肠道上皮细胞为了能抵抗微生物的侵犯,必须透过防御机制认出病原并做快速的反击。所述防御机制即为先天性免疫反应系统,它是以型态识别接受器(Pattern-recognition receptor,PRR)来识别微生物,它可以识别大多数微生物共有且必要的大分子,如革兰氏阴性菌(Gram-negative)细胞壁的成份多糖脂(Lipopolysaccharide,LPS)。近年来已知型态识别受器如何启动(活化)细胞。已知在果蝇细胞中,当受到感染之后,Toll蛋白质诱导抗真菌与抗细菌的肽。Medzhitov及Janeways等人发现在哺乳动物中,Toll样受体(Toll-like receptor,TLR)会诱导活化后天免疫反应所需的细胞激素与共刺激分子(Cell 91:295-298,1997)。由于TLR分子的细胞内段与IL-1受器相似(Toll-IL-1R homology),因此细胞内讯号传导的路径被认为是类似的。当TLR与内毒素结合时,会使得NF-kB移转至细胞核(Nuclear translocation)对其他免疫调节基因进行转录控制(transcription regulation)。结果就是启动前发炎细胞激素(proimflammatorycytokine)基因的表现、抗微生物肽的分泌,以及如IL-8,MIP,MCP-1等化学激素(chemokines)的分泌。这些化学激素(chemokines)负责活化巨噬细胞及自然杀手细胞(NK cell),到达被感染的区域,消灭受到感染的细胞(Cell 91:295-298,1997;Gurr.Opin.Immunol.14:103-110,2002)。Toll样受体除了活化先天性免疫力之外,也因为启动了NF-kB,造成前发炎细胞激素的分泌,间接活化了后天性免疫力。
人类细胞中至少有十种已知的TLR,而在TLR家族中以TLR-2、TLR-4及TLR-9的研究最多。已知TLR参与辨识多种病原,包括细菌与病毒。TLR-4是革兰氏阴性菌LPS的受器,TLR-2则是革兰氏阳性菌肽聚糖(peptidoglycan)的受器,同时也是结核杆菌脂肽(lipopeptide)的受器,而TLR-9则是含非甲基化磷化CG寡核苷酸(Unmethylated & phosphorylated cytosine-guanine oligonucleotide,CpG)的受器。(Curr.Opin.Immunol.14:103-110,2002)TLR-3可辨识双股RNA病毒(Nature 433:887-892,2005),而TLR-7可辨识单股RNA病毒(Proc Natl Acad SciU S A.101(15):5598-5603,2004)。当活化TLR讯息传递路径时,则诱导先天性免疫力或是抗病毒反应以保护自身。
在肠道上皮细胞中,正常情况下,TLR-3与TLR-5会持续表现,而TLR-2与TLR-4的表现量极少。(Infection and Immunity 68:7010-7017,2000)在肠道上皮细胞中,细菌的CpG寡核苷酸是TLR-9的配体(ligand),当受到细菌DNA的刺激时,上皮细胞会产生IL-8(FASEB J.17:1319-1321,2003)。再者,肠道表皮细胞并不会对所有的外来物质而进行诱导发炎,亦即肠道上皮细胞对于共生的微生物具有耐受性,而在潜在的病原条件或是自体免疫疾病下,肠道上皮细胞提供危险信号至抗原呈现细胞,因而藉由抗原呈现细胞诱发T细胞所参与的发炎反应(Cell118:229-241,2004)。
在正常稳定的情况下,TLR所辨识的共生微生物对于保护肠道免于受到损害扮演相当重要的角色(Cell 118:229-241,2004)。然而,在人类发炎性肠道疾病(Inflammatory bowel disease,IBD)中,由Th1所引起的病理现象是由于对微生物的异常黏膜免疫反应(Gastroenterol.Clin.North Am.31:41-62,2002)。这些发现显示TLR调控宿主与共生微生物之间的黏膜平衡。
已知口服中草药萃取物可调节免疫力,极可能是因为中草药萃取物透过肠道黏膜免疫而调节免疫力的发展。石斛(Dendrobium)属于兰科植物,性甘味甜微咸,为一种非常珍贵的中药材。有些中药药典揭露石斛(Dendrobium)物种可有效治疗黏膜疾病、胃病与眼疾。根据我们之前的研究显示Herba Dendrobii对于免疫系统疾病以及黏膜疾病具有治疗效果。
本发明是提供一种用于自石斛(Dendrobium)制备多糖的方法,且更提供由石斛(Dendrobium)所得多糖的医药使用。
发明内容
本发明的一目的是提供自植物制备多糖的方法。所述方法包含的步骤为a)以第一醇类萃取该植物,以获得一第一醇类萃取物以及剩余植材,b)以一溶剂萃取所述剩余植材,以获得一第二萃取物,以及c)以第二醇类沉淀所述第二萃取物,以获得所述多糖。
所述植物较佳是属于石斛(Dendrobium)属。
所述第一醇类较佳是甲醇。
所述溶剂较佳是水。
所述第二醇类较佳是乙醇。
根据本发明,在步骤b)中以所述溶剂萃取所述剩余植材后,所述方法更包含离心与过滤,以获得所述第二萃取物。
本发明的另一目的是提供一种用于治疗自体免疫疾病与黏膜疾病的组成物。所述组成物包含由一植物所制备的多糖,其中所述植物属于石斛(Dendrobium)属,以及与诱发所述自体免疫疾病相关的抗原。
所述多糖较佳是由本发明所提供的方法所制备而得。
根据本发明,所述自体免疫疾病是葡萄膜炎(uveitis)。
本发明的另一目的是提供一种治疗哺乳动物自体免疫疾病与黏膜疾病的方法。所述方法包含将一抗原与一多糖投予所述哺乳动物,其中所述抗原是关于所述自体免疫疾病的诱发,以及所述多糖是自石斛(Dendrobium)属的植物中制备而得。
根据本发明,以口服的方式投予所述多糖。
根据本发明,所述自体免疫疾病是葡萄膜炎(uveitis)。
本发明的另一目的是提供一种用于治疗哺乳动物自体免疫疾病与黏膜疾病的方法。所述方法包含将一多糖投予所述哺乳动物,其中所述多糖是自石斛(Dendrobium)属的植物中制备而得。
根据本发明,以口服的方式投予所述多糖。
根据本发明,所述自体免疫疾病是葡萄膜炎(uveitis)。
通过以下的详细说明与附随图式,可使本领域技术人员更清楚了解本发明的目的与优点。
附图概述
图1是说明IEC-6细胞以DeCaPS处理后,PCR分析细胞激素与抗微生物肽的mRNA表现。
图2是说明IEC-6细胞以DeCaPS处理后,PCR分析Toll样受体(Toll-likereceptor,TLR)的mRNA表现。
图3是说明C3H老鼠口服DeCaPS之后,以ConA刺激脾脏细胞行细胞分裂的效应。
图4是说明C3H老鼠口服DeCaPS之后,以GM-CSF共刺激骨髓细胞行细胞分裂的效应。
图5是说明C3H老鼠口服DeCaPS之后,PCR分析所取得的皮尔氏斑(Peyer’sPatch)与脾脏细胞中特定细胞激素的mRNA表现。
图6是说明C57BL/6j老鼠在有无口服DeCaPS下,口服白蛋白(ovalbumin)之后,分析肠液中针对白蛋白的IgA含量。
图7是说明C57BL/6j老鼠在有无口服DeCaPS下,口服白蛋白(ovalbumin)之后,分析血清中针对白蛋白的IgM含量。
图8是说明C57BL/6j老鼠在有无口服DeCaPS下,口服白蛋白(ovalbumin)之后,分析血清中针对白蛋白的IgG含量。
图9是说明以PCR分析C57BL/6j老鼠皮尔氏斑(Peyer’s Patch)中淋巴细胞的细胞激素表现。
图10是说明C57BL/6j老鼠的DTH反应。
图11A是一视网膜电流图,说明正常组老鼠闪动强度范围。
图11B是正常组老鼠的眼睛组织切片图。
图12A是一视网膜电流图,说明对照组老鼠闪动强度范围。
图12B是对照组老鼠的眼睛组织切片图。
图13A是一视网膜电流图,说明DC-10组老鼠闪动强度范围。
图13B是DC-10组老鼠的眼睛组织切片图。
图14A是一视网膜电流图,说明DC-40组老鼠闪动强度范围。
图14B是DC-40组老鼠的眼睛组织切片图。
图15A是一视网膜电流图,说明DC-160组老鼠闪动强度范围。
图15B是DC-160组老鼠的眼睛组织切片图。
图16A是说明图11A、12A、13A、14A与15A中a波的振幅。
图16B是说明图11B、12B、13B、14B与15B中b波的振幅。
本发明的最佳实施方案
请参阅以下实施例,以更进一步了解本发明。须注意的是以下本发明较佳实施例的说明仅作为阐示用途,而并不限制本发明的揭露形式。
本发明提供一种自植物制备多糖的方法,所包含的步骤为a)以第一醇类萃取该植物,以获得一第一萃取物以及剩余植材,b)以一溶剂萃取所述剩余植材,以获得一第二萃取物,以及c)以第二醇类沉淀所述第二萃取物,以获得所述多糖。
范例I:自石斛(Dendrobium)制备多糖
将10公斤的新鲜Herba Dendrobii干燥成为2.92公斤的干燥材料,而后以73.3公升的甲醇浸泡且萃取所述的干燥材料,而得到136.79公克的粗抽物以及剩余植材。将所述的剩余植材进行去甲醇制程,接着以水浸泡过夜。以55℃至60℃的热水萃取反应液30分钟,而后于10℃以离心机(ER-RC13C-124,HITACHI)转速5000转进行离心。离心后,以6微米的滤纸过滤上清液。以乙醇沉淀滤液,因而获得20.684克的多糖(而后称为DeCaPS)。
范例II:以DeCaPS处理的IEC-6细胞的免疫反应
a.培养IEC-6细胞
在37℃下,于含有5%CO2的培养箱中,将源自于正常老鼠小肠的IEC细胞培养于含有5%胎牛血清、4.5g/L葡萄糖、5μg/ml胎牛胰岛素与2mML-谷氨酰胺(Glutamine)的DMEM培养液中。
b.以DeCaPS处理IEC-6细胞
当6孔盘中长满IEC-6细胞时,分别以0μg/ml、1μg/ml、10μg/ml与100μg/ml浓度的DeCaPS处理IEC细胞6小时。
c.自以DeCaPS处理的IEC细胞分离总RNA
在以DeCaPS处理之后,收取IEC细胞并将其悬浮于1毫升的Ultraspec TMRNA分离试剂(美国Biotex laboratories公司),并以所述试剂中的标准程序取得总RNA并定量。
d.反转录并PCR分析细胞激素与Toll样受体
反应体积为26.5μl(微升),包含0.1微克的寡dT、5微克的所取得总RNA以及DEPC处理过的无菌水,于70℃反应10分钟。而后加入4微升的10mM dNTP、0.5微升的rRNAsin、1微升的AMV(禽类成髓细胞性白血病病毒(Avian myeloblastosisvirus,AMV)反转录酵素(10单位)以及8微升的5x RT缓冲液,使得总体积为40微升,并在42℃下反应60分钟,而后在90℃反应5分钟,藉此自反转录反应得到cDNA产物。接着,将0.5微升的10mM dNTP、0.5微升10x Prozyme缓冲液、引物(0.8微升的5μM sense DNA与0.8微升的5μM antisense DNA)以及无菌水加入2.5微升的所述cDNA产物,形成总体积25微升,并放置于DNA热循环器(Perkin-Elmer-Cetus)中培养,进行35循环的PCR反应。表一是说明包含目标基因的正股(sense)与反股(antisense)引物(序列编号1-32)的所述引物序列,以及对应的接合(annealing)温度。
表一
序列编号 | 目标基因(PCR产物大小) | 接合温度(℃) |
1,2 | β-actin(肌动蛋白)(510bps) | 57 |
3,4 | IL-1β563bps | 61 |
5,6 | IL-2(502bps) | 61 |
7,8 | IL-4(399bps) | 61 |
9,10 | I1-6(638bps) | 61 |
11,12 | IL-10(455bps) | 61 |
序列编号 | 目标基因(PCR产物大小) | 接合温度(℃) |
13,14 | TNF-α(308bps) | 57 |
15,16 | IFN-γ(460bps) | 61 |
17,18 | TGF-β(525bps) | 61 |
19,20 | 老鼠α-防卫素(900bps) | 59 |
21,22 | 老鼠血管生成素(900bps) | 59(热起始) |
23,24 | TLR2(495bps) | 55 |
25,26 | TLR4(508bps) | 57 |
27,28 | TLR5(737bps) | 59 |
29,30 | TLR7(729bps) | 59 |
31,32 | TLR9(725bps) | 60 |
请参阅图1,其是说明IEC-6细胞以DeCaPS处理后,以PCR分析细胞激素与抗微生物肽的mRNA表现。分别以浓度1μg/ml、10μg/ml与100μg/ml的DeCaPS处理6小时的IEC-6细胞,IEC-6细胞中TNF-α(序列编号:33)的mRNA表现量大约分别被抑制29%、20%与30%;然而,IEC-6细胞中IL-10(序列编号:34)的mRNA表现量大约分别上升9.89倍、6.55倍与1.77倍。这表示DeCaPS可诱导肠道上皮细胞提供耐受信号至免疫系统中的其他细胞,进而诱发TH2/3路径。此外,在以浓度1μg/ml、10μg/ml与100μg/ml的DeCaPS处理6小时后,IEC-6细胞中α-防卫素(序列编号:35)的mRNA表现量大约分别被抑制42%、33%与51%;然而,IEC-6细胞中血管生成素(序列编号:36)的mRNA表现量大约分别上升1.96倍、1.42倍与1.70倍。
请参阅图2,说明IEC-6细胞以DeCaPS处理后,以PCR分析Toll样受体(Toll-like receptor,TLR)的mRNA表现。在未处理DeCaPS的IEC-6细胞中,所表现的Toll样受体为TLR2(序列编号:37)、TLR4(序列编号:38)、TLR7(序列编号:39)以及TLR9(序列编号:40)。在以浓度1μg/ml、10μg/ml与100μg/ml的DeCaPS处理6小时后,IEC-6细胞中TLR4(序列编号:38)的mRNA表现量大约分别被抑制6%、16%与13%,IEC-6细胞中TLR5(序列编号:41)的mRNA表现量大约分别被抑制13%、37%与35%,IEC-6细胞中TLR7(序列编号:39)的mRNA表现量大约分别被抑制11%、7%与48%;然而,IEC-6细胞中TLR9(序列编号:40)的mRNA表现量大约分别上升2.21倍、1.09倍与3.56倍。这表示自石斛取得的多糖不仅抑制TNF-α(序列编号:33)的表现,也抑制TLR4(序列编号:38)、TLR5(序列编号:41)与TLR7(序列编号:39)的表现。
范例III:动物模式口服DeCaPS对于免疫系统的效应
将由范例I制备的DeCaPS,透过饮用水,以10毫克/公斤/日、50毫克/公斤/日以及250毫克/公斤/日的剂量喂食C3H老鼠(13周大)5天,而后牺牲老鼠以取得脾脏与骨髓。
a.以刀豆蛋白A(Concanavalin A,Con A)刺激自C3H老鼠所取得的脾脏细胞并进行MTT分析
自以DeCaPS处理的C3H老鼠所取得的脾脏细胞(4×105细胞/槽)培养于含有10%胎牛血清与浓度为1或5微克/毫升的刀豆蛋白A(Con A)的RPMI-1640培养液中,处理72小时,而后以1毫克/毫升的MTT处理3小时。而后,将含有50%DMF与20%SDS的溶解(lysis)缓冲液加入细胞培养中,进行反应16小时。分析反应在570纳米的吸光值,作为生长指标,如图3所示。
请参阅图3,其说明C3H老鼠口服DeCaPS之后,以ConA刺激来自经处理C3H老鼠的脾脏细胞行细胞分裂的效应。分别以口服剂量为10毫克/公斤/日、50毫克/公斤/日以及250毫克/公斤/日的DeCaPS处理C3H老鼠5天后,脾脏细胞对于1微克/毫升的ConA刺激反应大约被抑制28%、49%与30%。
b.GMCSF刺激自C3H老鼠所取得骨髓细胞的MTT分析
自口服DeCaPS的C3H老鼠的腿部,取得骨髓细胞。将所述骨髓细胞培养于含有2%FCS与4ng/ml GMCSF的α-MEM培养液中,而正对照组的骨髓细胞于含有2%FCS与20ng/ml GMCSF的α-MEM培养液中培养72小时。接着将培养液换为含有1mg/ml MTT与2%FCS的RPMI-1640处理骨髓细胞3小时,而后细胞以MTT溶解缓冲液(pH4.5,20%SDS与50%DMF)处理培养过夜。反应于570钠米分析吸光值,以代表生长指标,如图4所示。
请参阅图4,说明C3H老鼠口服DeCaPS处理后,以GM-CSF刺激得自C3H老鼠的骨髓细胞行细胞分裂的效应。分别以口服剂量为10毫克/公斤/日、50毫克/公斤/日以及250毫克/公斤/日的DeCaPS处理C3H老鼠5天后,骨髓细胞对于GM-CSF刺激的细胞分裂反应大约被提升1.71倍、1.62倍与1.76倍。
c.得自C3H老鼠的皮尔氏斑与脾脏细胞中,细胞激素的mRNA表现
自口服DeCaPS处理的C3H老鼠,取得皮尔氏斑与脾脏细胞。以范例II中的方法,用PCR分析皮尔氏斑与脾脏细胞中特定细胞激素的mRNA,而PCR的结果如图5所示。
请参阅图5,说明C3H老鼠口服DeCaPS处理后,PCR分析自C3H老鼠所取得的皮尔氏斑(Peyer’s Patch)与脾脏细胞中特定细胞激素的mRNA表现,其中1-4分别代表口服DeCaPS剂量为0毫克/公斤/日、10毫克/公斤/日、50毫克/公斤/日以及250毫克/公斤/日的C3H老鼠。
在C3H老鼠口服DeCaPS 5天后,皮尔氏斑中IL-4(序列编号:42)、IL-6(序列编号:43)、IL-1β(序列编号:44)、IFN-γ(序列编号:45)与TGF-β(序列编号:46)的mRNA表现量增加,如图5所示。在C3H老鼠口服剂量为10毫克/公斤/日或50毫克/公斤/日的DeCaPS达5天后,IL-4(序列编号:42)的mRNA表现量分别增加为2.64倍与2.46倍。在C3H老鼠口服剂量为10毫克/公斤/日、50毫克/公斤/日或250毫克/公斤/日的DeCaPS达5天后,IL-6(序列编号:43)的mRNA表现量分别增加为2.61倍、3.99倍与5.35倍,IL-1β(序列编号:44)的mRNA表现量分别增加为1.83倍、2.00倍与1.11倍,IFN-γ(序列编号:45)的mRNA表现量分别增加为3.47倍、5.47倍与5.57倍,以及TGF-β(序列编号:46)的mRNA表现量分别增加为2.38倍、2.54倍与1.89倍。由于皮尔氏斑是决定对于抗原的免疫反应的主要位置,所以对于IL-4(序列编号:42)与IL-6(序列编号:43)的增加,会诱发Th2路径,透过IL-1β(序列编号:44)增加,可活化T辅助细胞分泌细胞激素,例如TGF-β(序列编号:46),以及TGF-β(序列编号:46)诱导IgA类转换的B细胞分泌IgA,以抑制某些免疫反应。
在C3H老鼠口服DeCaPS处理达5天后,脾脏细胞中IL-1β(序列编号:44)、IL-4(序列编号:42)与TGF-β(序列编号:46)的mRNA表现量受到抑制,如图5所示。在C3H老鼠以口服剂量为10毫克/公斤/日、50毫克/公斤/日或250毫克/公斤/日的DeCaPS处理达5天后,IL-1β(序列编号:44)的mRNA表现量大约抑制32%、43%与79%,且IL-4(序列编号:42)的mRNA表现量大约抑制7%、67%与14%。在C3H老鼠口服剂量为50毫克/公斤/日或250毫克/公斤/日的DeCaPS达5天后,TGF-β(序列编号:46)的mRNA表现量大约抑制27%与44%,以及IFN-γ(序列编号:45)的mRNA表现量大约抑制33%与97%。然而,在C3H老鼠以口服剂量为10毫克/公斤/日、50毫克/公斤/日或250毫克/公斤/日的DeCaPS处理达5天后,IL-6(序列编号:43)的mRNA表现量增加为1.84倍、1.4倍与1.23倍。值得注意的是对于DeCaPS处理并没有明显的细胞反应,且此现象是与对于ConA刺激的反应一致。
范例IV:以DeCaPS于动物模式中增加口服耐受性
由于已知动物受到卵白蛋白(OVA)免疫化可建立自体免疫疾病的动物模式(TheJournal of Pharmacology and Experimental Therapeutics 288:849-857,1999),所以本发明建立以OVA诱导自体免疫疾病的老鼠,并且以DeCaPS在OVA诱导自体免疫疾病的老鼠上促进口服耐受性,如以下的说明。在第4天与第5天,将C57/BL6j老鼠(65周大)透过饮用水,口服喂食0.5毫克/毫升卵白蛋白(OVA),以及在第3-7天,将DeCaPS投予C57/BL6j老鼠作为佐剂(adjuvant),剂量分别为10毫克/公斤/日、40毫克/公斤/日与160毫克/公斤/日。在第8天时,以CFA为佐剂的50微克OVA,以i.p.注射投予老鼠作为抗原,在第22天时,于血液收集中侦测到针对OVA的IgG与IgM,在第24天时,将50微克的OVA以i.p.注射投予老鼠,在第30天时,侦测到针对OVA的抗体;在第32天,将老鼠牺牲,以获得肠黏膜的肠液与肺黏膜,而后侦测到针对OVA的IgA。详细的实验过程如表II中所述。
表二、在动物模式中口服含/不含DeCaPS的OVA
在第32天取得老鼠肠黏膜肠液,其中测得肠液中针对卵白蛋白的IgA量,如图6所示。请参阅图6,以OVA与DeCaPS(40毫克/公斤/日)处理的C57/BL6j老鼠中由肠黏膜所分泌的IgA增加为1.9倍(p<0.01),以及以OVA与DeCaPS(160毫克/公斤/日)处理的C57/BL6j老鼠中由肠黏膜所分泌的IgA增加为4.35倍(p<0.001)
在第22天与第30天,检测血清中的IgM抗体,如图7所示。相较于第22天对照组所表现的IgM抗体量,正常组所表现的IgM抗体量大约被抑制49%(p<0.05),正对照组所表现的IgM抗体量大约被抑制87%(p<0.05),DC-1组所表现的IgM抗体量大约被抑制46%(p<0.02),DC-2组所表现的IgM抗体量大约被抑制88%(p<0.001),以及DC-3组所表现的IgM抗体量大约被抑制86%(p<0.001)。再者,第30天时,相较于对照组所表现的IgM抗体量,正常组所表现的IgM抗体量大约被抑制47%(p<0.01),正对照组所表现的IgM抗体量大约被抑制72%(p<0.001),DC-1组所表现的IgM抗体量大约被抑制38%(p<0.01),DC-2组所表现的IgM抗体量大约被抑制58%(p<0.01),以及DC-3组所表现的IgM抗体量大约被抑制71%(p<0.001)。
在第22天与第30天,检测血清中的IgG抗体,如图8所示。相较于第22天对照组所表现的IgG抗体量,正对照组所表现的IgG抗体量大约被抑制94%(p<0.01),DC-1组所表现的IgG抗体量大约被抑制67%(p<0.01),DC-2组所表现的IgG抗体量大约被抑制76%(p<0.01),以及DC-3组所表现的IgG抗体量大约被抑制88%(p<0.001)。再者,相较于第30天对照组所表现的IgG抗体量,正对照组所表现的IgG抗体量大约被抑制75%(p<0.001),DC-2组所表现的IgG抗体量大约被抑制62%(p<0.001),以及DC-3组所表现的IgG抗体量大约被抑制63%(p<0.001)。
此外,在第32天由老鼠取得皮尔氏斑,萃取皮尔氏斑中淋巴球的RNA并分析细胞激素。皮尔氏斑中淋巴球的细胞激素表现,如图9所示,其中A行代表正常组,B行代表对照组,C行代表正对照组,D行代表DC-1组,E行代表DC-2组,以及F行代表DC-3组。PCR放大程序为在94℃变性(denature)45秒,在61℃接合(annealing)45秒以及在72℃延长(extension)1分钟。在所述PCR程序中有37循环。以2%的洋菜胶体,电泳分离PCR产物,以及将胶体以溴化乙锭(ethidium bromide)染色并以UV灯照射。
值得注意的是相较于对照组,在DC-3组中TGF-β(序列编号:46)表现量大约被抑制30%,DC-3组中IL-4(序列编号:42)的表现量大约增加为2.2倍,以及DC-3组中IL-10(序列编号:34)的表现量大约增加为1.3倍。相较于对照组,DC-2组中IL-2(序列编号:47)的表现量大约增加为1.4倍,以及DC-2组中IL-4(序列编号:42)的表现量大约增加为1.6倍。再者,相较于对照组,DC-1组中IL-4(序列编号:42)的表现量大约增加为1.4倍,以及DC-1组中IL-6(序列编号:43)的表现量大约增加为1.3倍。
皮尔氏斑中淋巴球的IL-4(序列编号:42)与IL-6(序列编号:43)mRNA表现量上升。必须要强调的是当抗原诱发T细胞或是B细胞透过机制回到小肠时,皮尔氏斑是决定对于抗原的免疫反应的位置,因应IL-4(序列编号:42)与IL-6(序列编号:43)的增加,活化Th2路径以产生抗体,血清中的IgG与IgM表现量受到抑制,以抑制过敏反应,并且达到口服耐受性。
承上所述,得自于石斛(Dendrobium)的多糖可抑制胰脏中T细胞的细胞分裂反应(mitogenic response);然而,骨髓中颗粒细胞(granulocyte)与巨噬细胞(macrophage)则是会受到石斛(Dendrobium)多糖的的活化。换句话说,可藉由口服石斛多糖而抑制自免疫疾病中被活化的T细胞;然而,藉由口服石斛多糖而活化颗粒细胞系(granulocyte lineage),进以藉由促进先天性免疫力(innateimmunity),而防止病原入侵。
关于肠道免疫,IL-4(序列编号:42)、IL-6(序列编号:43)、IL-1β(序列编号:44)、IFN-γ(序列编号:45)与TGF-β(序列编号:46)的mRNA表现量增加,而诱发肠道内的Th2/Th3路径,因而形成口服耐受性。根据以石斛多糖所处理的IEC-6细胞中TNF-α(序列编号:33)、TLR2(序列编号:37)、TLR4(序列编号:38)、TLR5(序列编号:41)与TLR7(序列编号:39)的表现,显示藉由石斛多糖,Toll样受体(toll-like receptor)所传达的讯息可被调节为免疫抑制型反应或是抗发炎反应,以促进口服耐受性的相关讯息,亦即Th2/3路径,并且在感染病原状态下,例如自体免疫疾病与黏膜疾病,保持体内黏膜的平衡(mucosal homeostasis)。有趣的是如范例II所述,口服石斛多糖可诱导具有抗微生物活性的血管生成素(angiogenin)的表现。因此,口服石斛多糖不仅促进口服耐受性,更可诱发先天性免疫力(innate immunity)以防止病原入侵。根据这些发现,石斛多糖可有效治疗自体免疫疾病与黏膜疾病,例如发炎性肠道疾病(inflammatory bowel disease,IBD),以减缓长期发炎与伤害。
已知血管生成素(angiogenin)具有的活性不仅可以对抗肠道微生物,例如乳酸球菌(Enterococcus faecalis),更可以对抗引起人类系统感染的微生物,例如白色念珠菌(Candida albicans)与肺炎链球菌(Streptococcus pneumoniae)。(Nat.Immunol.4:269-273,2003)在临床研究中,女性的白带(leucorrhea)是多种微生物的表浅阴道感染(polymicrobial,superficial vaginal infection),通常是受到细菌感染,例如阴道伽氏杆菌(G.vaginalis)、念珠菌(Candida spp.)、白色念珠菌(C.albicans)、阴道毛滴虫(T.vaginalis)、链球菌族群D(Streptococcusgroup D)、b型溶血性链球菌(Streptococcus b hemolytic)、大肠杆菌与克雷白式菌(Klebsiella spp.)等。(Salud publica Mex vol.45 suppl.5,pS694-S697,2003)很明显地,由微生物如白色念珠菌(Candida albicans)所引起的女性白带可藉由口服石斛多糖,诱导血管生成素(angiogenin)的活性而得到舒缓。
范例IV:以DeCaPS治疗自体免疫疾病
实验用的自体免疫葡萄膜炎(Uveitis)是T细胞所参与的自体免疫疾病,作为一些眼睛自体免疫疾病的模式。已经确认实验用的自体免疫葡萄膜炎是以140-kD的糖脂蛋白“光受体间维生素A酸结合蛋白质(interphotoreceptor retinoidbinding protein,IRBP)”免疫诱导而形成。亦为已经确定的是可藉由IRBP肽1-20(序列编号:48:GPTHLFQPSLVLDMAKVLLD),此为IRBP的第1至20个胺基酸,进以诱导自体免疫葡萄膜炎。此外,IRBP肽1-20在老鼠与人类皆相同(conserved)。(Investigative Ophthalmology & Visual Science 41(1):127-131,2000)所以,在本发明中使C57BL/6j老鼠口服IRBP肽以建立自体免疫模式。
a.合成IRBP肽
以Fmoc化学肽合成器(PS3)合成IRBP肽1-20(序列编号:48:GPTHLFQPSLVLDMAKVLLD),以Agilent HPLC纯化并以Brukeer esquire 2000 MS进行纯化。
b.投予IRBP与DeCaPS
将无特定病原(specific-pathogen-free,SPF)的C57BL/6j老鼠随机分组,分为正常组、对照组、DC-10组、DC-40组以及DC-160组,其中各组有6只老鼠。以i.p.注射的方式,将含有人类IRBP肽(序列编号:48)(150微克/鼠)与CFA(1∶1体积/体积)的0.2毫升乳化液(emulsion)中投予除正常组外的各组SPF鼠。透过饮用水,以10毫克/公斤/天剂量的DeCaPS喂食DC-10组的老鼠28天,以40毫克/公斤/天剂量的DeCaPS喂食DC-40组的老鼠28天,以160毫克/公斤/天剂量的DeCaPS喂食DC-160组的老鼠28天。以视网膜电流图(electro-retinogram,ERG)分析老鼠的视网膜功能,并且在第28天将老鼠牺牲,以获得其眼睛进行生物分析与组织病理鉴定。所述实验过程如以下表三所述。
表三、在动物模式中投予/不投予DeCaPS治疗自体免疫疾病
组别 | 老鼠数 目 | 第0天的 ERG鉴 定 | 第1天以 IRBP免疫 (immunizatio n) | DeCaPS (第1-28 天)毫克/ 公斤/天 | DTH分析 (第21与23天) | 第28天ERG & 组织病理 |
正常 | 6 | + | - | - | + | + |
控制 | 6 | + | + | - | + | + |
DC-10 | 6 | + | + | 10 | + | + |
DC-40 | 6 | + | + | 40 | + | + |
DC-160 | 6 | + | + | 160 | + | + |
c.迟发型过敏免疫反应(Delayed type hypersensitivity,DTH)测试
在以IRBP肽免疫后的第21天,以IFA(20微升)中乳化的20微克IRBP肽皮下注射于老鼠左脚掌。以IFA注射右脚掌。在48小时后,以尺测量脚掌的厚度。
请参阅第10图,显示老鼠的DTH反应。相对于注射磷酸盐缓冲溶液(PBS)的老鼠的脚掌厚度增加量,以脚掌厚度增加量呈现DTH反应。值得注意的是投予DeCaPS(160毫克/公斤/天)的老鼠的脚掌增加量是明显降低。
d.视网膜电流图分析
将老鼠置于暗室2小时,而后以戊巴比妥酸钠(sodium pentobarbital)麻醉。老鼠的角膜被麻醉且瞳孔放大。以闪光刺激视网膜,并且将视网膜对于闪光的反应记录成为视网膜电流图。所述视网膜电流图显示光受体的作用与视网膜近端,如两极细胞与Müller细胞的功能。视网膜电流图用以反应整个视网膜的状态。在视网膜电流图中,典型为负向a波而后为正向b波。A波前缘是测量光受体层锥细胞与杆细胞的活性,而b波则是反应内核层中两极细胞的作用。
在第28天随机自正常组选取的2只老鼠,其视网膜电流图的结果分别显示于图11A的上部与下部,其中闪光是起始于时间100毫秒且闪光期间约为600毫秒。在第28天随机自正常组选取的2只老鼠,其眼睛的组织病理鉴定分别显示于图11B的上部与下部(400倍放大),其中光受体层标示为P、外核层标示为ONL且内核层标示为INL。
在第28天随机自对照组选取的2只老鼠,其视网膜电流图的结果分别显示于图12A的上部与下部,其中闪光是起始于时间100毫秒且闪光期间约为600毫秒。在第28天随机自对照组选取的2只老鼠,其眼睛的组织病理鉴定分别显示于图12B的上部与下部(400倍放大)。显示由于以IRBP肽免疫(immunization),对照组老鼠的光受体层(P)、外核层(ONL)与内核层(INL)受到严重的伤害。
在第28天随机自DC-10组选取的2只老鼠,其视网膜电流图的结果分别显示于图13A的上部与下部,其中闪光是起始于时间100毫秒且闪光期间约为600毫秒。在第28天随机自DC-10组选取的2只老鼠,其眼睛的组织病理鉴定分别显示于图13B的上部与下部(400倍放大)。显示由于以IRBP肽免疫(immunization)后并口服DeCaPS(10毫克/公斤/天)28天,DC-10组老鼠的光受体层(P)、外核层(ONL)与内核层(INL)受到严重的伤害。
在第28天随机自DC-40组选取的2只老鼠,其视网膜电流图的结果分别显示于图14A的上部与下部,其中闪光是起始于时间100毫秒且闪光期间约为600毫秒。在第28天随机自DC-40组选取的2只老鼠,其眼睛的组织病理鉴定分别显示于图14B的上部与下部(400倍放大)。显示由于以IRBP肽免疫(immunization)后并口服DeCaPS(40毫克/公斤/天)28天,DC-40组老鼠的光受体层(P)、外核层(ONL)与内核层(INL)仅受到轻微的伤害。
在第28天随机自DC-160组选取的2只老鼠,其视网膜电流图的结果分别显示于图15A的上部与下部,其中闪光是起始于时间100毫秒且闪光期间约为600毫秒。在第28天随机自DC-160组选取的2只老鼠,其眼睛的组织病理鉴定分别显示于图15B的上部与下部(400倍放大)。显示由于以IRBP肽免疫(immunization)后并口服DeCaPS(160毫克/公斤/天)28天,DC-160组老鼠的光受体层(P)、外核层(ONL)与内核层(INL)并未受到伤害。
据此,在以IRBP肽免疫(immunization)后,发现内核层有更多的细胞死亡,而死亡的细胞并不会下陷至外核层。亦发现IRBP肽处理会伤害内核层中的细胞,然而以160毫克/公斤/天剂量的处理可明显防止细胞自内核层脱落。
此外,在图16A中比较图11A、12A、13A、14A与15A中所示的a波(统计p<0.02),以及在图16B中比较图11A、12A、13A、14A与15A中所示的b波(统计p<0.02)。要强调的是以IRBP肽免疫的对照组老鼠的a波明显低于正常组老鼠的a波;然而,相较于正常组,以DeCaPS(40毫克/公斤/天)处理的老鼠,明显可防止细胞自内核层脱落。再者,以DeCaPS(160毫克/公斤/天)处理的老鼠,其a波与b波的振幅几乎等于正常组老鼠的a波与b波振幅。更要进一步强调的是以IRBP肽免疫所造成的伤害可由自石斛(Dendrobium)所制备的多糖(160毫克/公斤/天)处理而挽救。换句话说,口服由石斛所制备的多糖可使视网膜免于受到由IRBP所诱导的发炎。
根据上述实验,本发明是提供一种组合物,用于治疗自体免疫疾病与黏膜疾病,其中所述组合物包含由石斛(Dendrobium)所制备的多糖以及诱导所述自体免疫疾病的抗原,这是由于自石斛(Dendrobium)所制备的多糖可促进口服耐受性的诱发且促进先天性免疫力。再者,本发明是提供仅包含自石斛(Dendrobium)所制备的多糖的组合物,用于治疗自体免疫疾病与黏膜疾病,这是由于自石斛(Dendrobium)所制备的多糖可单独诱导口服耐受性且调节先天性免疫力。
虽然本发明已说明于上述较佳实施例中,然而可以理解的是本发明并不会因为所揭露的实施例而受到限制。相反地,本发明可包含不同的修饰与相似的配置,却仍不脱本发明权利要求的精神与范围,根据对于本发明权利要求最宽广的解释,可包含所有的修饰与类似的架构。
Claims (3)
1.一种萃取自石斛(Dendrobii Herba)的多糖在制备用于治疗哺乳动物自体免疫葡萄膜炎的药物中的用途。
2.如权利要求1的用途,其中所述多糖通过如下方法制备,所述方法包含的步骤为:
(a)以甲醇萃取石斛,以获得一第一萃取物;
(b)以水萃取所述第一萃取物,以获得一第二萃取物;以及
(c)以乙醇沉淀所述第二萃取物,以获得所述多糖。
3.如权利要求1的用途,其中所述药物是一口服药物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/121,721 | 2005-05-04 | ||
US11/121,721 US20060251739A1 (en) | 2005-05-04 | 2005-05-04 | Composition and method for treating autoimmune disease and mucosal disorder |
PCT/CN2006/000895 WO2006116950A2 (fr) | 2005-05-04 | 2006-04-30 | Composition, son procede de preparation et son utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101180068A CN101180068A (zh) | 2008-05-14 |
CN101180068B true CN101180068B (zh) | 2010-09-15 |
Family
ID=37308335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800152597A Expired - Fee Related CN101180068B (zh) | 2005-05-04 | 2006-04-30 | 萃取自石斛的多糖在制备用于治疗哺乳动物自体免疫葡萄膜炎的药物中的用途 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20060251739A1 (zh) |
EP (1) | EP1920778B1 (zh) |
JP (1) | JP4820406B2 (zh) |
KR (1) | KR101029525B1 (zh) |
CN (1) | CN101180068B (zh) |
AT (1) | ATE476191T1 (zh) |
AU (1) | AU2006243596B2 (zh) |
CA (1) | CA2608630C (zh) |
DE (1) | DE602006015971D1 (zh) |
NZ (1) | NZ563947A (zh) |
WO (1) | WO2006116950A2 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551547B2 (en) * | 2006-11-10 | 2013-10-08 | Murray Goulburn Co-Operative Co., Limited | Process for the preparation of angiogenin |
KR101760758B1 (ko) | 2008-05-14 | 2017-07-24 | 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 | 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용 |
US7935684B2 (en) * | 2008-07-22 | 2011-05-03 | National Yang-Ming University | Method for treating allergic diseases |
AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
JP7064820B2 (ja) | 2016-03-31 | 2022-05-11 | ピアス株式会社 | 育毛剤、並びにε‐ポリリジンおよび/またはシャクヤク抽出物の使用 |
TWI723344B (zh) | 2019-02-20 | 2021-04-01 | 安益藥業股份有限公司 | 使用印防己毒烷型結構之倍半萜類化合物用於製備護眼的醫藥組合物的用途 |
CN113337566A (zh) * | 2021-06-22 | 2021-09-03 | 安徽利民生物科技股份有限公司 | 一种石斛多肽的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1457808A (zh) * | 2002-05-14 | 2003-11-26 | 上海市中药研究所 | 一种铁皮石斛复方制剂及制备和应用 |
CN1555854A (zh) * | 2004-01-07 | 2004-12-22 | 北京乾露春科技有限公司 | 一种制备脉络宁注射制剂的工艺方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9024320D0 (en) * | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
US20050058730A1 (en) * | 2003-09-15 | 2005-03-17 | Xushan Wan | Compositions and methods for preventing or treating eyestrain |
CN1246026C (zh) * | 2004-02-09 | 2006-03-22 | 金陵药业股份有限公司 | 一种中药口服液及其在制药中的应用 |
JP4422573B2 (ja) * | 2004-05-05 | 2010-02-24 | 國立陽明大學 | 霍山デンドロビーコーリイス抽出物及びその調製方法 |
-
2005
- 2005-05-04 US US11/121,721 patent/US20060251739A1/en not_active Abandoned
-
2006
- 2006-04-30 EP EP06741791A patent/EP1920778B1/en not_active Not-in-force
- 2006-04-30 AT AT06741791T patent/ATE476191T1/de not_active IP Right Cessation
- 2006-04-30 KR KR1020077028292A patent/KR101029525B1/ko not_active IP Right Cessation
- 2006-04-30 WO PCT/CN2006/000895 patent/WO2006116950A2/zh not_active Application Discontinuation
- 2006-04-30 NZ NZ563947A patent/NZ563947A/en not_active IP Right Cessation
- 2006-04-30 CA CA2608630A patent/CA2608630C/en not_active Expired - Fee Related
- 2006-04-30 DE DE602006015971T patent/DE602006015971D1/de active Active
- 2006-04-30 CN CN2006800152597A patent/CN101180068B/zh not_active Expired - Fee Related
- 2006-04-30 AU AU2006243596A patent/AU2006243596B2/en not_active Ceased
- 2006-04-30 JP JP2008509290A patent/JP4820406B2/ja not_active Expired - Fee Related
-
2007
- 2007-09-05 US US11/899,590 patent/US7939110B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1457808A (zh) * | 2002-05-14 | 2003-11-26 | 上海市中药研究所 | 一种铁皮石斛复方制剂及制备和应用 |
CN1555854A (zh) * | 2004-01-07 | 2004-12-22 | 北京乾露春科技有限公司 | 一种制备脉络宁注射制剂的工艺方法 |
Non-Patent Citations (2)
Title |
---|
黄民权等.铁皮石斛多糖对小白鼠白细胞数和淋巴细胞移动抑制因子的影响.天然产物研究与开发8 3.1996,8(3),39-41. |
黄民权等.铁皮石斛多糖对小白鼠白细胞数和淋巴细胞移动抑制因子的影响.天然产物研究与开发8 3.1996,8(3),39-41. * |
Also Published As
Publication number | Publication date |
---|---|
KR101029525B1 (ko) | 2011-04-18 |
WO2006116950A3 (fr) | 2007-01-11 |
ATE476191T1 (de) | 2010-08-15 |
NZ563947A (en) | 2009-12-24 |
KR20080037610A (ko) | 2008-04-30 |
EP1920778A2 (en) | 2008-05-14 |
US20090099128A1 (en) | 2009-04-16 |
JP2008540348A (ja) | 2008-11-20 |
JP4820406B2 (ja) | 2011-11-24 |
EP1920778B1 (en) | 2010-08-04 |
AU2006243596A1 (en) | 2006-11-09 |
US7939110B2 (en) | 2011-05-10 |
EP1920778A4 (en) | 2009-09-02 |
WO2006116950A2 (fr) | 2006-11-09 |
US20060251739A1 (en) | 2006-11-09 |
DE602006015971D1 (de) | 2010-09-16 |
CA2608630C (en) | 2011-03-15 |
AU2006243596B2 (en) | 2009-11-12 |
CN101180068A (zh) | 2008-05-14 |
CA2608630A1 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101180068B (zh) | 萃取自石斛的多糖在制备用于治疗哺乳动物自体免疫葡萄膜炎的药物中的用途 | |
Renz et al. | The immunological basis of the hygiene hypothesis | |
Rao et al. | Effect of Achyranthes aspera on the immunity and survival of Labeo rohita infected with Aeromonas hydrophila | |
Li et al. | Protective effects of γ-irradiated Astragalus polysaccharides on intestinal development and mucosal immune function of immunosuppressed broilers | |
EP0681479B1 (en) | Immunotherapeutic composition | |
Barbour et al. | A review of approaches targeting the replacement of coccidiostat application in poultry production | |
Thompson | Immunology: improvement of innate and adaptive immunity | |
Yang et al. | Structural characterization of an immunostimulating polysaccharide from the stems of a new medicinal Dendrobium species: Dendrobium Taiseed Tosnobile | |
Wang et al. | Immunoadjuvant effects of bacterial genomic DNA and CpG oligodeoxynucleotides on avian influenza virus subtype H5N1 inactivated oil emulsion vaccine in chicken | |
CN103096923A (zh) | 新型免疫佐剂化合物及其用途 | |
Song et al. | Effects of four different adjuvants separately combined with Aeromonas veronii inactivated vaccine on haematoimmunological state, enzymatic activity, inflammatory response and disease resistance in crucian carp | |
Jain et al. | Immunostimulants: concepts, types and functions | |
Bi et al. | Yeast cell wall upregulated cell-mediated immune responses to Newcastle disease virus vaccine | |
JP2006241023A (ja) | 消化管組織における抗菌ペプチドの発現誘導または産生促進剤 | |
Tukmechi et al. | The effects of short-and long-term diet supplementation with Iranian propolis on the growth and immunity in rainbow trout (Oncorhynchus mykiss) | |
Ekstedt | Studies on Immunity to Staphylococcal Infection in Mice: IV. The Role of Specific and Nonspecific Immunity [with Discussion] | |
CN104208678A (zh) | 一种兽用抗病毒组合物、冻干粉、制备方法及应用 | |
Spînu et al. | Vegetal extracts influence in vitro on the cell-mediated immunity in carnivores depending on health status, target species and plant taxonomy | |
Santurio et al. | Effect of yeast purified β-glucan in experimental treatment of pythiosis in rabbits | |
Ma et al. | Adjuvant properties of water extractable arabinoxylans with different structural features from wheat flour against model antigen ovalbumin | |
CN104208683B (zh) | 一种抗鸭病毒性疾病的药物组合物、冻干粉、制备方法及应用 | |
Paśnik | Non specific vaccines–immunostimulation in patients with recurrent respiratory infections | |
Bertók et al. | Nomenclature and significance of innate/natural immune mechanisms and of species specific resistance | |
JP2019156759A (ja) | 多糖組成物 | |
JP2023550276A (ja) | 免疫調節物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100915 Termination date: 20190430 |
|
CF01 | Termination of patent right due to non-payment of annual fee |